<code id='C15A075659'></code><style id='C15A075659'></style>
    • <acronym id='C15A075659'></acronym>
      <center id='C15A075659'><center id='C15A075659'><tfoot id='C15A075659'></tfoot></center><abbr id='C15A075659'><dir id='C15A075659'><tfoot id='C15A075659'></tfoot><noframes id='C15A075659'>

    • <optgroup id='C15A075659'><strike id='C15A075659'><sup id='C15A075659'></sup></strike><code id='C15A075659'></code></optgroup>
        1. <b id='C15A075659'><label id='C15A075659'><select id='C15A075659'><dt id='C15A075659'><span id='C15A075659'></span></dt></select></label></b><u id='C15A075659'></u>
          <i id='C15A075659'><strike id='C15A075659'><tt id='C15A075659'><pre id='C15A075659'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:explore    Page View:71979
          2020 Biogen
          Steven Senn/AP

          Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

          This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

          advertisement

          STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Jerome Adams on the need for new antivirals for Covid
          Jerome Adams on the need for new antivirals for Covid

          PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

          read more
          Patient advocates debate FDA's accelerated approval process
          Patient advocates debate FDA's accelerated approval process

          Fromleft,STAT'sAllisonDeAngelis,ALSadvocateCathyCollet,Yale'sGreggGonsalves,SickCells'AshleyValentin

          read more
          New air purifier tech could be key to improving indoor air quality
          New air purifier tech could be key to improving indoor air quality

          AdobeUntiltheearly20thcentury,Americaregularlyexperiencedbrutallydestructiveurbanfires.Conflagration

          read more

          States should stop sabotaging methadone treatment reform

          Somearguethattakingmethadoneathomeisfarbetterthantrudgingtoacliniceveryday.KevinD.Liles/APSincetheFo